Short-Term Debt to Capital: Acasti Pharma Inc. (ACST)

Acasti Pharma laboratories operate on a strict schedule for developing new therapies, eliminating any equipment failures. The business relies on innovative drug delivery methods for treating orphan diseases and the pursuit of major partners. This chart available on GURU.Markets shows the 0.00 metric, while the efficiency of cardiology tool deliveries to medical centers is guaranteed by strict oversight of the entire distribution chain.

For Acasti Pharma (ACST), which relies on external financing due to a lack of commercial products, the short-term debt-to-equity chart serves as a survival indicator. This metric is calculated as the ratio of liabilities maturing within one year to equity, measuring liquidity dependence on short-term loans; a decrease in this ratio minimizes default risk, confirming the company's resilience during periods of clinical trial uncertainty.